MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

Metabolism. Meloxicam is eliminated almost entirely by hepatic metabolism: two-thirds by cytochrome (CYP) P450 enzymes (CYP2C9 two-thirds and CYP3A4 one-third) and one-third by other pathways, such as peroxidase oxidation. Meloxicam is almost completely metabolised to four pharmacologically inactive metabolites. The major metabolite, 5'-carboxymeloxicam (60% of dose), from CYP2C9 mediated metabolism, is formed by oxidation of an intermediate metabolite 5'-hydroxymethylmeloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies suggest that CYP2C9 plays an important role in this metabolic pathway, with a minor contribution from the CYP3A4 isoenzyme. The patient's peroxidase activity is probably responsible for the other two metabolites which account for 16% and 4% of the administered dose respectively. If you have any of these symptoms, do not drive, operate machinery or do anything else that could be dangerous. Side effects The following is a list of adverse events occurring in < 1% of patients, which may be causally related to the administration of Movalis. The information is based on clinical trials involving patients who have been treated with daily oral doses of Movalis 7.5 or 15 mg tablets over a period of up to 18 months (mean duration of treatment 127 days). Tell your doctor if you are taking any medicines used to treat high blood pressure and some other heart problems such as ACE inhibitors, angiotensin receptor antagonists and diuretics (also called fluid or water tablets). Lithium. NSAIDs have been reported to increase lithium plasma levels (via decreased renal excretion of lithium), which may reach toxic values. The concomitant use of lithium and NSAIDs is not recommended. If this combination appears necessary, lithium plasma concentrations should be monitored carefully during the initiation, adjustment and withdrawal of meloxicam treatment.

MOVALIS may hide some of the signs of an infection (eg. pain, fever, redness and swelling). You may think, mistakenly, that you are better or that the infection is not serious. Things you must not do Effects on fertility. Oral treatment with meloxicam at doses up to 5 mg/kg/day in female rats (approximately 2.7 times the human dose based on BSA) and up to 9 mg/kg/day (approximately 5 times the human dose based on BSA) in male rats did not affect mating behaviour or fertility. Selective inhibition of the cyclooxygenase-2 (COX-2) isoenzyme, relative to COX-1, by meloxicam has been demonstrated in vitro on various cell systems: guinea pig macrophages, bovine aortic endothelial cells (for testing of COX-1 activity), mouse macrophages (for testing for COX-2 activity), and human recombinant enzymes expressed in cos-cells and in human whole blood. If any of the following happen, stop taking it and tell your doctor immediately, or go to Accident and Emergency at the nearest hospital:

Volume of Distribution

Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. As with most NSAIDs, occasional increases in serum transaminase levels, increases in serum bilirubin or other liver function parameters, as well as increases in serum creatinine and blood urea nitrogen as well as other laboratory disturbances, have been reported. The majority of these instances involved transitory and slight abnormalities. Should any such abnormality prove significant or persistent, the administration of Movalis should be stopped and appropriate investigations undertaken. Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs. Movalis Hypertension interaction

Suplimentele alimentare sunt medicamente naturale care vin in ajutorul formarii de energie. Acestea se gasesc sub forma de tablete, sirop, baton etc. si furnizeaza organismului substante nutritive necesare dietei zilnice. Paediatric use. Movalis is not recommended for use in children and adolescents under 18 years of age (see Contraindications). disfuncţie renală, care poate evolua în insuficienţă renală cu oligo-hidramnios; mama şi nou-născutul, la sfârşitul sarcinii, la:daca dupa utilizarea acidului acetilsalicilic sau a altor medicamente antiinflamatoare nesteriodiene ati avut vreunul dintre urmatoarele semne: respiratie suieratoare, apasare in piept, senzatie de lipsa de aer (astm bronsic); obstructie la nivelul nasului datorita inflamatiei mucoasei nazale (polipi nazali); eruptii trecatoare pe piele sau urticarie; aparitia brusca a tumefactiilor la nivelul pielii sau mucoaselor, cum este tumefactia din jurul ochilor, fetei, buzelor, gurii si gatului, putand determina dificultati in respiratie (edem angioneurotic); tulburări ale numărului elementelor sanguine, incluzând formula leucocitară, leucopenia şi trombocitopenia. Administrarea concomitentă a unui medicament potenţial mielotoxic, metotrexat în special, pare a fi un factor favorizant pentru apariţia citopeniei.

Exacerbations of Osteoarthritis: 7.5 mg/day (half a 15 mg tablet); if necessary, in the absence of improvement, the dose may be increased to 15 mg/day.

Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDSs (see 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: The onset of the reaction occurring in the majority of cases within the first month of treatment. Movalis should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. Lactose monohydrate. Movalis tablets 7.5 mg contain 47 mg lactose monohydrate and Movalis tablets 15 mg contain 20 mg lactose monohydrate per maximum recommended daily dose. Patients with rare hereditary conditions of galactose intolerance, e.g. galactosaemia, should not take this medicine. Oral hypoglycaemics. Interactions via CYP 2C9 can be expected in combination with medicinal products such as oral anti-diabetics (sulfonylureas), which may lead to increased plasma levels of these drugs and meloxicam. Patients concomitantly using meloxicam with sulfonylureas should be carefully monitored for hypoglycemia. Do not give your medicine to anyone else, even if they have the same condition as you. Things to be careful of